Corvus Pharmaceuticals Inc Asset Resilience Ratio

Latest as of June 2026: 82.05%

Corvus Pharmaceuticals Inc asset resilience ratio. Corvus Pharmaceuticals Inc (CRVS) has an Asset Resilience Ratio of 82.05% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CRVS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$196.32 Million

Cash + Short-term Investments

Total Assets

$239.27 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of Corvus Pharmaceuticals Inc (2015–2025)

Asset resilience ratio of Corvus Pharmaceuticals Inc from 2015 to 2025. This chart shows how Corvus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Corvus Pharmaceuticals Inc for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Corvus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Corvus Pharmaceuticals Inc asset portfolio.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$196.32 Million	82.05%
Total Liquid Assets	$196.32 Million	82.05%

Asset Resilience Insights

Very High Liquidity: Corvus Pharmaceuticals Inc maintains exceptional liquid asset reserves at 82.05% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Corvus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Corvus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Corvus Pharmaceuticals Inc Asset Resilience Ratio by Year (2015–2025)

Corvus Pharmaceuticals Inc asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Corvus Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	73.36%	$52.17 Million	$71.12 Million	+10.63pp
2024-12-31	62.73%	$43.22 Million	$68.91 Million	+30.83pp
2023-12-31	31.89%	$14.53 Million	$45.55 Million	-10.81pp
2022-12-31	42.71%	$29.14 Million	$68.24 Million	+37.23pp
2021-12-31	5.48%	$5.99 Million	$109.45 Million	-27.03pp
2020-12-31	32.51%	$27.80 Million	$85.53 Million	-54.56pp
2019-12-31	87.07%	$72.83 Million	$83.65 Million	+23.29pp
2018-12-31	63.77%	$75.40 Million	$118.23 Million	+16.35pp
2017-12-31	47.43%	$44.95 Million	$94.78 Million	-45.22pp
2016-12-31	92.65%	$129.85 Million	$140.15 Million	+0.95pp
2015-12-31	91.69%	$90.28 Million	$98.46 Million	--

pp = percentage points

About Corvus Pharmaceuticals Inc

NASDAQ:CRVS USA Biotechnology

Market Cap

$889.16 Million

Market Cap Rank

#9268 Global

#2603 in USA

Share Price

$10.57

Change (1 day)

+7.53%

52-Week Range

$6.50 - $25.52

All Time High

$25.52